No more annual flu shot? New target for universal influenza vaccine

CastleVax Inc. Receives BARDA Project NextGen Award Valued at up to $338 Million to Advance Intranasal NDV-based COVID-19 Booster Vaccine into Phase 2b Clinical Efficacy Testing

Promising Results of Next-Generation Intranasal COVID-19 Booster Vaccine: Implications for Infection Prevention and Transmission

Mount Sinai Announces the Formation of CastleVax Inc., a Clinical-Stage Infectious Diseases Company Developing Novel Vaccines and Therapeutics, Targeting Pandemic Threats and Diseases of Unmet Medical Need

Mount Sinai to Lead Discussions on Transgender Health, Psychedelic Therapeutics and Long COVID at the 2022 Aspen Ideas: Health and Aspen Ideas Festival

Mount Sinai Researchers Awarded $16 Million to Develop Antivirals Against Viruses With Pandemic Potential

Scientific Consortium Established by National Institutes of Health Provides Real-Time Risk Assessment of SARS-CoV-2 Variants on Immune Protection

"Immunity To Coronavirus Lingers For Months In Recovered Patients - Study"

"You're going to need more than one coronavirus shot. One dose of a vaccine probably won't be enough, experts say." - Aylin Woodward

Mount Sinai seeks EUA from Food and Drug Administration for potential quantitative serologic test for COVID-19

Mount Sinai’s Blood Test to Detect Antibodies to COVID-19 Receives Emergency Use Authorization From U.S. Food and Drug Administration